Navigation Links
A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to,Sustained Reductions in Blood Glucose Levels for 6 Months,Post-treatment in Type 2 Diabetes Patients

e specifically, the mean HbA1c level among treated patients was reduced 0.43%, 0.94% (p<0.05), 1.09% (p<0.05), 1.12% (p<0.05), 1.21% (p<0.05), and 1.14% in months 1, 2, 3, 4, 5, and 6 post-treatment, respectively. In contrast, the mean HbA1c levels of the placebo group ranged from a reduction of 0.1% to an increase of 1.0% over the same period. In addition to the HbA1c reductions, the data demonstrated decreases in fasting blood glucose levels as well as improvements in glucose tolerance over a six month period following treatment with E1-I.N.T.(TM). Trends in increased insulin levels as measured with an oral glucose tolerance test were also observed, particularly in patients where the HbA1c levels decreased over 1% with E1-I.N.T.(TM) therapy. These data are consistent with the increased glucose control observed in diabetes animal models where a short treatment with E1-I.N.T.(TM) resulted in a sustained increase in beta cell mass and function. These clinical improvements, including HbA1c reductions greater than 1% in patients six month post-treatment, highlight the potential that E1-I.N.T.(TM) therapy could provide patients significant clinical benefit in excess of 6 months.

Safety and Tolerability Findings:

There were no serious adverse events noted during the study. As described in Transition's press release of March 5th, 2007, the most common adverse events reported by patients receiving E1-I.N.T.(TM), were nausea, diarrhea, headaches and vomiting which were generally mild to moderate in nature. The majority of these adverse events were reported during the treatment period with the occurrence of adverse events in the post-treatment phase being similar in both the treated and placebo groups.

Next Steps:

In this study, the tolerable dosing levels of E1-I.N.T.(TM) and the efficacy parameters to be employed in future clinical studies were established. Building upon these sustained efficacy findings, the next steps in clinical development w
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy.
2. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
3. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
4. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
5. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
6. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
7. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
8. Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers
9. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
10. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
11. MediQuest Concludes Confirmatory Phase III Study of Raynaud’s Therapy
Post Your Comments:
(Date:6/30/2015)...  EnteroMedics Inc. (NASDAQ: ETRM ), a developer ... treat obesity, metabolic diseases, and other gastrointestinal disorders, announced ... 40,229,886 units. Each unit consists of one share of ... purchase one share of common stock, and 0.50 of ... common stock, at a purchase price of $0.87 per ...
(Date:6/30/2015)... Calif. and COPENHAGEN, Denmark ... Inc. , a global leader in clinical and commercial ... today that, as part of its global manufacturing capacity ... North American manufacturing facility in Bothell, Washington ... 6Pack™ facility.  The Bioreactor 6Pack™ configuration consists of six ...
(Date:6/29/2015)... Mordor Intelligence presents their Global Pharmaceutical Packaging Market ... Metal) - ByType of Packaging (Ampules, Blister Packs, Bottles, Canisters, ... By Geographical Region ( North America , ... Latin America , Middle East ... Industry Value Chain Analysis, Porter,s 5 Force Analysis, Drivers, Restraints, ...
Breaking Medicine Technology:EnteroMedics Inc. Announces Pricing of $35.0 Million Public Offering of Common Stock and Warrants 2EnteroMedics Inc. Announces Pricing of $35.0 Million Public Offering of Common Stock and Warrants 3CMC Biologics Expands GMP Manufacturing Capacity in the United States 2CMC Biologics Expands GMP Manufacturing Capacity in the United States 3Global Pharmaceutical Packaging Market - North America and Europe Expected to Lead Followed by the Asia Pacific Market 2Global Pharmaceutical Packaging Market - North America and Europe Expected to Lead Followed by the Asia Pacific Market 3
... Cepheid (Nasdaq: CPHD ) today announced that ... Vice President of Infectious Disease Research and Development, reporting ... offers an impressive menu of eleven highly regarded Xpert® ... aggressively to extend our leadership with next-generation products, including ...
... 2011 In a recent announcement by Neurelis, ... positive clinical results in a Phase I pharmacokinetic ... at Particle Sciences.  In the Phase 1 clinical ... that reported in the literature for Diastat® (rectal ...
Cached Medicine Technology:Cepheid Appoints Vice President of Infectious Disease Research & Development 2Cepheid Appoints Vice President of Infectious Disease Research & Development 3Particle Sciences Develops Proprietary Nasal Delivery Formulation Used in Neurelis' Recently Announced Successful Phase I Pharmacokinetic Study of NRL-01 (intranasal diazepam) 2
(Date:6/30/2015)... Tennessee (PRWEB) , ... June ... ... of CorrectChemo®, the drug response profiling test to help oncologists provide personalized ... , “The CorrectChemo® assay provides the oncologist with valuable insight on ...
(Date:6/30/2015)... ... June 30, 2015 , ... iData ... has launched a new reimbursement insurance policy tracking and analysis service. Reimbursement ... insurance policy and rate updates in real-time from hundreds of insurance companies covering ...
(Date:6/30/2015)... ... June 30, 2015 , ... Micro Com ... provides high quality record management services for patient records. Medical imaging includes services ... by physicians and clinics. , With the increase in the acceptance level ...
(Date:6/30/2015)... Angeles, California (PRWEB) , ... June 30, 2015 ... ... applauds Congressmen Joe Kennedy III (D-MA) and Danny Davis (D-IL) for writing ... speed up its investigation into the nation’s largest behavioral healthcare system, Universal Health ...
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... ... announced today a partnership with Knockout Zone Miami (KO Zone), a ... and conditioning specialist and CrossFit Coach, Diego de Vera. The partnership will provide ...
Breaking Medicine News(10 mins):Health News:Correct Chemo Joins NextGxDx Online Genetic Testing Marketplace 2Health News:Correct Chemo Joins NextGxDx Online Genetic Testing Marketplace 3Health News:iData Research Introduces New Medical Insurance Reimbursement Policy & Rate Tracker Subscription Service 2Health News:Micro Com Systems Ltd Now Specializes in Medical Imaging 2Health News:CCHR Seeks Public Input on Psychotropic Drug Billing and Psychiatric Abuse: Applauds Congressmen for Behavioral Hospitals Investigation Call 2Health News:CCHR Seeks Public Input on Psychotropic Drug Billing and Psychiatric Abuse: Applauds Congressmen for Behavioral Hospitals Investigation Call 3Health News:CCHR Seeks Public Input on Psychotropic Drug Billing and Psychiatric Abuse: Applauds Congressmen for Behavioral Hospitals Investigation Call 4Health News:CCHR Seeks Public Input on Psychotropic Drug Billing and Psychiatric Abuse: Applauds Congressmen for Behavioral Hospitals Investigation Call 5Health News:Top Sports Nutrition Brand, Liporidex, Announces Partnership With Leading Boxing, CrossFit and MMA Gym, Knockout Zone of Miami 2Health News:Top Sports Nutrition Brand, Liporidex, Announces Partnership With Leading Boxing, CrossFit and MMA Gym, Knockout Zone of Miami 3
... ... proudly announces a new fund-raising campaign - the sale of ... living with HIV/AIDS and extreme poverty in Uganda. The money raised by ... and provide them with additional nutritional support. The MPWN "BONO" bracelets ...
... Jenifer Goodwin HealthDay Reporter , WEDNESDAY, June ... in the development of alopecia areata, a disorder that ... genes are already associated with other autoimmune diseases, including ... may already be in the pipeline that could benefit ...
... ... stage a performance of the Radio City Rockettes in Vienna for the 2010 Life Ball on ... New York, NY ... performance of the Radio City Rockettes in Vienna for the 2010 Life Ball on July 17th, ...
... 2010 The Florida Biomedical Research Program has awarded ... from the Florida campus of The Scripps Research Institute. ... an associate professor in the Scripps Research Department of ... Bannister, assistant professor of medicinal chemistry and associate scientific ...
... the Stanford University School of Medicine have identified a ... because the existence of such a cell in the ... It may also explain why current immunotherapies are largely ... "These cells lack the traditional melanoma cell surface ...
... Dotinga HealthDay Reporter , WEDNESDAY, June 30 (HealthDay News) ... much later on in life, a new study suggests it might ... Canadian researchers believe they,ve found a link between exercise in adolescence ... The study doesn,t definitively prove that exercise lowers the risk of ...
Cached Medicine News:Health News:Mulago Positive Women's Network Announce Their "BONO" Bracelet Fundraiser to Benefit HIV+ Women in Uganda 2Health News:Mulago Positive Women's Network Announce Their "BONO" Bracelet Fundraiser to Benefit HIV+ Women in Uganda 3Health News:Genes Tied to Hair Loss Disorder 2Health News:Genes Tied to Hair Loss Disorder 3Health News:DVF To Bring The Radio City Rockettes To Vienna's Life Ball 2Health News:DVF To Bring The Radio City Rockettes To Vienna's Life Ball 3Health News:Scripps Research scientists share $2 million in Florida state research grants 2Health News:Melanoma-initiating cell identified by Stanford scientists 2Health News:Melanoma-initiating cell identified by Stanford scientists 3Health News:Melanoma-initiating cell identified by Stanford scientists 4Health News:Exercise May Guard Girls Against Dementia in Senior Years 2
... The table-mounted hip ... hands-free exposure for total ... to accommodate individual surgeon ... of any size. Hand-held ...
... gelatinase-associated lipocalin, lipocalin-2) is a new early ... renal failure with a >90% positive predictive ... urine, as early as 2 hours after ... diagnostic marker for acute renal failure. ,Quantitative ...
... "Beautiful tissue is how one neurosurgeon describes ... Needle. By "beautiful he means a,cleaner cut ... are,functions of the needles optimized vacuum and ... captive locking thumb nut holds vacuum,in the ...
CVC 123 is an assayed quality control material used for confirming the calibration and linearity of blood gas, electrolyte, and metabolite instrumentation....
Medicine Products: